Evgen Pharma plc

Equities

EVG

GB00BSVYN304

Biotechnology & Medical Research

Delayed London S.E. Other stock markets 06:06:38 2024-04-19 am EDT			5-day change	1st Jan Change
0.775 ^GBX	0.00%		0.00%	-51.56%

Apr. 04	Northcoders launches bootcamp; Schroder invests	AN
Apr. 04	Evgen Pharma Concludes Retail Offer of Shares	MT

Evgen Pharma : Posting of Circular and Timing of General Meeting

April 18, 2019 at 03:13 pm EDT

Evgen Pharma plc

('Evgen Pharma', or the 'Company')

Posting of Circular

and

Timing of General Meeting

Evgen Pharma(AIM: EVG), a clinical stage drug development company focused on the treatment of cancer and neurological conditions, announces that further to its announcement of the Placing yesterday (the 'Placing Announcement'), a shareholder circular, including the notice of General Meeting, and a form of proxy are today being posted to shareholders. The shareholder circular and notice of General Meeting will be made available on the Company's website www.evgen.com

Furthermore, since the posting of the Placing Announcement yesterday, the timing of the General Meeting has been changed and will now take place on 8 May 2019 at 11.00 a.m. at the offices of finnCap, 60 New Broad Street, London EC2M 1JJ.

Capitalised terms used in this announcement shall have the same meanings as the definitions in the Placing Announcement.

For further information please visit www.evgen.com or contact:

Evgen Pharmaplc Dr Stephen Franklin, CEO Richard Moulson, CFO www.evgen.com	c/o +44 (0) 20 7466 5000
finnCap Geoff Nash, Teddy Whiley (Corporate Finance) Alice Lane, Manasa Patil (ECM) www.finncap.com	+44 (0) 20 7220 0500
WG Partners LLP Nigel Barnes, Claes Spång	+44 (0) 20 3705 9330
Buchanan Mark Court, Sophie Wills, Tilly Abraham evgen@buchanan.uk.com	+44 (0) 20 7466 5000

About Evgen Pharma plc

Evgen Pharma is a clinical stage drug development company whose lead programmes are in breast cancer and subarachnoid haemorrhage, a type of stroke. The Company's core technology is Sulforadex®, a method for synthesising and stabilising the naturally occurring compound sulforaphane and novel proprietary analogues based on sulforaphane. The lead product, SFX-01, is a patented composition of synthetic sulforaphane and alpha-cyclodextrin.

The Group commenced operations in January 2008 and has its headquarters at The Colony, Wilmslow, Cheshire, and its registered office is at the Liverpool Science Park, Liverpool. It joined the AIM market of the London Stock Exchange in October 2015 and trades under the ticker symbol EVG.

For further information, please visit:www.evgen.com

Attachments

Original document
Permalink

Disclaimer

Evgen Pharma plc published this content on 18 April 2019 and is solely responsible for the information contained herein. Distributed by Public, unedited and unaltered, on 18 April 2019 16:37:04 UTC

Latest news about Evgen Pharma plc

Northcoders launches bootcamp; Schroder invests	Apr. 04	AN
Evgen Pharma Concludes Retail Offer of Shares	Apr. 04	MT
Evgen Pharma Signs Takeover Deal with Chronos Therapeutics; Raises Capital Via Share Issue, Subscription	Mar. 20	MT
EARNINGS AND TRADING: Ten Lifestyle sees profit up but sales flat	Mar. 19	AN
Evgen Pharma plc agreed to acquire Chronos Therapeutics Ltd. from group of shareholders for £3.4 million.	Mar. 18	CI
Evgen Pharma finds evidence of SFX-01 activity in colon cancer models	Feb. 27	AN
Evgen Pharma plc Announces That the Laboratories of Professor Grace Chen, Associate Professor Justin Colacino, and Professor Duxin Sun At the University of Michigan, Usa Have Observed Activity of Sfx-01 in Models of Colon Cancer	Feb. 27	CI
Evgen Pharma shares up on studies into SFX-01 product progressing well	Feb. 19	AN
Evgen Pharma plc Announces That the Laboratory of Dr Marjolein Geurts, Neuro-Oncologist At the Erasmus University Medical Centre Has Observed Continuing Activity of Sfx-01 in Gbm Cells	Feb. 19	CI
Apax opts against lifting offer; DCI enters loan deal	Feb. 09	AN
FTSE 100 falls at end of tepid week	Feb. 09	AN
Evgen Pharma Issues Notice of Dispute to Stalicla Over Missed Milestone Payment	Feb. 09	MT
Evgen partner raises USD17.4 million to support pipeline	Jan. 16	AN
Evgen Pharma plc announced that it has received $17.4 million in funding from Stalicla SA	Jan. 15	CI
Evgen appoints Toni Hanninen as permanent CFO	Dec. 22	AN
Evgen Pharma Interim CFO to Assume Post Permanently	Dec. 22	MT
Evgen Pharma plc Appoints Toni hänninen as Permanent Chief Financial Officer, Effective 1 January 2024	Dec. 22	CI
Evgen Pharma plc Announces Changes to its Board	Dec. 22	CI
Acuity RM wins contract; Georgia Capital ups earnings	23-10-31	AN
Earnings Flash (EVG.L) EVGEN PHARMA Reports Fiscal H1 Revenue GBP396,000	23-10-31	MT
Earnings Flash (EVG.L) EVGEN PHARMA Reports Fiscal H1 Loss GBX-0.53	23-10-31	MT
Evgen Pharma plc Reports Earnings Results for the Half Year Ended September 30, 2023	23-10-31	CI
Evgen Pharma plc Announces Erasmus Medical Center Commences Sfx-01 Glioblastoma Studies	23-10-26	CI
Evgen showcases importance of new enteric-coated formulation	23-10-19	AN
FTSE 100 Closes Down 0.2% Despite Rebound Driven by Energy Stocks	23-09-05	DJ

Chart Evgen Pharma plc

Duration

Period

More charts

Company Profile

Evgen Pharma plc is a United Kingdom-based clinical-stage drug development company. The Company is focused on the development of sulforaphane-based medicines for the treatment of cancer and inflammatory diseases. The Company's core technology is Sulforadex, which is a method for synthesizing and stabilizing the naturally occurring compound sulforaphane and novel proprietary analogues based on sulforaphane. Its asset, SFX-01, is a composition of synthetic sulforaphane and alpha-cyclodextrin and has undergone clinical trials for oestrogen-positive metastatic breast cancer. SFX-01 exploits sulforaphane's activity in three separate biochemical pathways, such as inhibition of STAT3 and SHP2, of importance in controlling cancers metastases, and up-regulation of Nrf2, a pathway of significance in several different diseases. Its pipeline includes breast cancer, glioblastoma, hematological malignancies, and analogues. It also has a licensing in neurodevelopmental disorders and schizophrenia.

Sector

Biotechnology & Medical Research

Calendar

2024-06-11 - Q4 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Ratings for Evgen Pharma plc

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

EPS Revisions

Estimates Revisions

Annual profits - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
EVGEN PHARMA PLC	-51.56%	4.13M
VERTEX PHARMACEUTICALS INCORPORATED	-3.30%	102B
REGENERON PHARMACEUTICALS, INC.	+1.79%	96.07B
ARGENX SE	-1.11%	21.66B
BIONTECH SE	-18.35%	20.77B
GENMAB A/S	-8.19%	18.53B
WUXI APPTEC CO., LTD.	-40.31%	16.91B
BEIGENE, LTD.	-26.84%	13.79B
NEUROCRINE BIOSCIENCES, INC.	+0.59%	13.33B
SAREPTA THERAPEUTICS, INC.	+20.86%	10.94B

Bio Therapeutic Drugs